About Script Wolverine: The BPC-157 TB-500 Record, Filed

What this site is

Script Wolverine files the BPC-157 TB-500 research — the two-peptide Wolverine blend — as a curated listing: each finding, dose parameter, and regulatory mark entered as its own cited record. It is a listing, not a service. No clinic, pharmacy, or compounding bench stands behind the keyline; the site makes nothing and sells nothing. It writes no prescription, offers no diagnosis or dosing, and keeps no clinicians. Every entry is a summary of published science with the source attached.

The listing format is the point — a reader sees at a glance whether a claim rests on confirmed preclinical evidence, on a human-data gap, or on the combination’s complete absence of controlled trials, the way a property portal files a listing with a photo, a status, and a record.

Why "Script," and what it does not mean

The "script" in the name is editorial framing — a position this publisher occupies relative to the prescription-and-access landscape, where the regulatory status of unapproved peptides is the central question. It is not a claim that this site writes prescriptions, fills them, or arranges access. We do not offer treatment, consultation, or prescription services, and the /legal-status page is general information about the regulatory landscape, not medical or legal advice.

What we do offer is a careful reading. We foreground the things the marketing tends to bury: that most BPC-157 and TB-500 evidence is rodent and single-compound, that the blend itself has never been tested in a controlled trial, that the "TB-500" most efficacy data describe is actually full-length Thymosin Beta-4, and that both constituents currently sit in FDA 503A Category 2. The record is interesting enough that it does not need inflating.

How the record is sourced

Every quantitative claim on this site maps to a numbered citation on the references page — peer-reviewed journals, recent systematic and narrative reviews, and FDA primary sources. Where the literature is thin or silent, we say so rather than filling the gap with extrapolation. When studies disagree, or when a finding comes from a single research group, we note it. The listing format makes those caveats first-class entries, not footnotes.